Unfavorable response to capmatinib for MET exon14 skipping after first-line osimertinib in a patient with EGFR-mutated lung adenocarcinoma: A case report and literature review

被引：0

作者：

Araki, Taisuke ^{[1
]}

Kanda, Shintaro ^{[2
]}

Yazaki, Tatsuya ^{[1
]}

Hirabayashi, Taro ^{[1
]}

Komatsu, Masamichi ^{[1
]}

Sonehara, Kei ^{[1
]}

Tateishi, Kazunari ^{[1
]}

Hanaoka, Masayuki ^{[1
]}

机构：

[1] Shinshu Univ, Sch Med, Dept Internal Med 1, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan

[2] Shinshu Univ, Sch Med, Dept Hematol & Med Oncol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan

来源：

RESPIRATORY INVESTIGATION | 2024年 / 62卷 / 04期

关键词：

exon14; skipping; Osimertinib; Capmatinib; Resistance; MET; CANCER;

D O I：

10.1016/j.resinv.2024.05.009

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

MET exon14 skipping mutations (METex14s) are rarely reported as a potential resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs). The efficacy of targeted therapy against METex14s emerging after osimertinib resistance is uncertain. Herein, we report a case of EGFR-mutated metastatic lung adenocarcinoma in which METex14 was detected in a re-biopsy upon first-line osimertinib resistance. The patient received capmatinib monotherapy as third-line therapy, which was ineffective, followed by an exceptional response to salvage therapy with afatinib. This report highlights the heterogeneity of EGFR-TKI resistance and that targeting rare resistance mechanisms remains challenging.

引用

页码：677 / 680

页数：4

共 10 条

[1] Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance [J].

Araki, Taisuke ;

Kanda, Shintaro ;

Horinouchi, Hidehito ;

Ohe, Yuichiro .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (07) :547-561

[2] MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression [J].

Awad, Mark M. ;

Oxnard, Geoffrey R. ;

Jackman, David M. ;

Savukoski, Daniel O. ;

Hall, Dimity ;

Shivdasani, Priyanka ;

Heng, Jennifer C. ;

Dahlberg, Suzanne E. ;

Anne, Pasi A. J. ;

Verma, Suman ;

Christensen, James ;

Hammerman, Peter S. ;

Sholl, Lynette M. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07) :721-+

[3] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer [J].

Leonetti, Alessandro ;

Sharma, Sugandhi ;

Minari, Roberta ;

Perego, Paola ;

Giovannetti, Elisa ;

Tiseo, Marcello .

BRITISH JOURNAL OF CANCER, 2019, 121 (09) :725-737

[4] A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation [J].

Pinquie, Francois ;

Cortot, Alexis B. ;

Chevalier, Louise-Marie ;

Morel, Alain ;

Sandrini, Jeremy ;

Guguen, Camille ;

Morvan, Benjamin ;

Molinier, Olivier .

CLINICAL LUNG CANCER, 2022, 23 (02) :E131-E134

[5] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC [J].

Ramalingam, S. S. ;

Vansteenkiste, J. ;

Planchard, D. ;

Cho, B. C. ;

Gray, J. E. ;

Ohe, Y. ;

Zhou, C. ;

Reungwetwattana, T. ;

Cheng, Y. ;

Chewaskulyong, B. ;

Shah, R. ;

Cobo, M. ;

Lee, K. H. ;

Cheema, P. ;

Tiseo, M. ;

John, T. ;

Lin, M-C ;

Imamura, F. ;

Kurata, T. ;

Todd, A. ;

Hodge, R. ;

Saggese, M. ;

Rukazenkov, Y. ;

Soria, J-C ;

Boyer, Michael ;

Lee, Chee ;

Hughes, Brett ;

O'Byrne, Kenneth ;

Briggs, Peter ;

Milward, Michael ;

John, Thomas ;

Demedts, Ingel ;

Vansteenkiste, Johan ;

Bustin, Frederique ;

Barrios, Carlos Henrique ;

Timcheva, Constanta ;

Butts, Charles ;

Goss, Glenwood ;

Juergens, Rosalyn ;

Leighl, Natasha ;

Cheng, Susanna ;

Burkes, Ronald ;

Zhou, Caicun ;

Zhang, Helong ;

Shu, Yongqian ;

Cheng, Ying ;

Zhou, Qing ;

Li, Wei ;

Feng, Guosheng ;

He, Yong .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01) :41-50

[6] Mesenchymal-Epithelial Transition Exon 14 Skipping Mutation and Amplification in 5,008 Patients With Lung Cancer [J].

Song, Yaolin ;

Li, Guangqi ;

Ju, Kun ;

Ran, Wenwen ;

Zhao, Han ;

Liu, Xianglan ;

Hou, Mingyu ;

He, Yulu ;

Chen, Yang ;

Zang, Guoliang ;

Xing, Xiaoming .

FRONTIERS IN ONCOLOGY, 2021, 11

[7] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer [J].

Soria, J. -C. ;

Ohe, Y. ;

Vansteenkiste, J. ;

Reungwetwattana, T. ;

Chewaskulyong, B. ;

Lee, K. H. ;

Dechaphunkul, A. ;

Imamura, F. ;

Nogami, N. ;

Kurata, T. ;

Okamoto, I. ;

Zhou, C. ;

Cho, B. C. ;

Cheng, Y. ;

Cho, E. K. ;

Voon, P. J. ;

Planchard, D. ;

Su, W. -C. ;

Gray, J. E. ;

Lee, S. -M. ;

Hodge, R. ;

Marotti, M. ;

Rukazenkov, Y. ;

Ramalingam, S. S. ;

Boyer, Michael ;

Lee, Chee ;

Hughes, Brett ;

O'Byrne, Kenneth ;

Briggs, Peter ;

Milward, Michael ;

John, Thomas ;

Demedts, Ingel ;

Vansteenkiste, Johan ;

Bustin, Frederique ;

Barrios, Carlos Henrique ;

Timcheva, Constanta ;

Butts, Charles ;

Goss, Glenwood ;

Juergens, Rosalyn ;

Leighl, Natasha ;

Cheng, Susanna ;

Burkes, Ronald ;

Zhou, Caicun ;

Zhang, Helong ;

Shu, Yongqian ;

Cheng, Ying ;

Zhou, Qing ;

Li, Wei ;

Feng, Guosheng ;

He, Yong .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02) :113-125

[8] Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer [J].

Suzawa, Ken ;

Offin, Michael ;

Schoenfeld, Adam J. ;

Plodkowski, Andrew J. ;

Odintsov, Igor ;

Lu, Daniel ;

Lockwood, William W. ;

Arcila, Maria E. ;

Rudin, Charles M. ;

Drilon, Alexander ;

Yu, Helena A. ;

Riely, Gregory J. ;

Somwar, Romel ;

Ladanyi, Marc .

JCO PRECISION ONCOLOGY, 2019, 3 :1-8

[9] Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation [J].

Takamori, Shinkichi ;

Seto, Takashi ;

Yamaguchi, Masafumi ;

Kinoshita, Fumihiko ;

Fujishita, Takatoshi ;

Ito, Kensaku ;

Toyozawa, Ryo ;

Shoji, Fumihiro ;

Okamoto, Tatsuro .

FRONTIERS IN ONCOLOGY, 2022, 12

[10] Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report [J].

Xiang, Siqi ;

Zeng, Liang ;

Xiang, Mingjun ;

Zhang, Yongchang .

HELIYON, 2023, 9 (11)

← 1 →